Related Experiment Video
Updated: Apr 24, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Beyond BRAF: where next for melanoma therapy?
I V Fedorenko1, G T Gibney2, V K Sondak2
1The Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Melanoma treatment advances, including BRAF inhibitors, offer hope but face resistance. Future strategies focus on combination therapies and personalized medicine for BRAF-mutant, NRAS-mutant, and wild-type melanoma.
Area of Science:
- Oncology
- Dermatology
- Precision Medicine
Background:
- Melanoma treatment has seen significant progress with targeted therapies, particularly BRAF inhibitors.
- BRAF and MEK inhibitor combinations have improved outcomes for BRAF-mutant melanoma patients.
- However, treatment resistance remains a major challenge, limiting long-term efficacy.
Purpose of the Study:
- To review current and future combination strategies for BRAF-mutant melanoma.
- To explore emerging therapeutic options for NRAS-mutant and BRAF/NRAS-wild-type melanoma.
- To highlight advancements in personalized therapy for melanoma.
Main Methods:
- Review of recent scientific literature on melanoma targeted therapies.
- Analysis of clinical trial data for combination strategies.
- Discussion of emerging therapeutic targets and personalized medicine approaches.
Main Results:
- BRAF/MEK inhibitor combinations show promise but are not universally effective.
- Resistance mechanisms necessitate novel therapeutic combinations.
- Personalized medicine approaches are crucial for optimizing treatment outcomes.
Conclusions:
- Combination therapies are essential for overcoming treatment resistance in melanoma.
- Targeting NRAS-mutant and wild-type melanoma requires distinct strategies.
- Personalized treatment strategies will continue to advance melanoma care.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

